COMPOSITIONS, CONTAINING BISMUTH, FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS

Abstract: The subject invention encompasses methods for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering bismuth to the subject.

Description: COMPOSITIONS , CONTAINING BISMUTH , FOR THE PREVENTION AND TREATMENT OF GASTROIN ¬ TESTINAL DISORDERS BACKGROUND OF THE INVENTION While many industrialized countries have come to regard infection by intestinal helminths as a problem of impoverished developing countries, this is far from true. The incidence of gastrointestinal infection by parasitic intestinal helminths continues to present a serious health concern. The World Health Organization and other authorities estimate that well over two billion of the population are infected annually with intestinal helminths. Manual Of Clinical Microbiology. Sixth Edition, 1141-1142. Worldwide, five hundred to eight hundred million are estimated to be infected with Tήchuris trichiura, and nine hundred million with hookworm. Id- Treatment of helminth infections has had modest success due to the complexity of the parasitic life cycles of the organisms i.e., egg, first-stage larva, second-stage larva, third-stage larva, free-form, etc. In addition, an increasing display of resistance to commonly used antihelminthic agents further hinders the likelihood of successful treatment of helminth infections. Therefore, the need for effective antihelminthic therapies continues to grow. It has been discovered by the present invention that the administration of bismuth salts may be effective for the prevention and/or treatment of gastrointestinal disorders caused or mediated by one or more intestinal helminths. Thus, an object of the present invention is to provide a safe and effective method of preventing and/or treating gastrointestinal disorders caused or mediated by intestinal helminths. A further object of the invention is to provide such a method comprising the administration of bismuth. These and other objects of the present invention will become readily apparent from the detailed description which follows. SUMMARY OF THE INVENTION The present invention relates to a method for treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering to the subject from about 50 milligrams to about 5000 milligrams of bismuth, per day, for from about 1 to 56 days. The present invention also relates to a method for prevention in a human or lower animal of a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering to the subject from about 50 milligrams to about 5000 milligrams of bismuth, per day, for from about 1 to 28 days. DETAILED DESCRIPTION OF THE INVENTION The methods of the present invention comprise the prevention and/or treatment of gastrointestinal disorder caused or mediated by one or more intestinal helminths. Such gastrointestinal disorders are prevented and/or treated by the administration of bismuth. The components of the present invention are more fully defined below. Gastrointestinal Disorder The term "gastrointestinal disorder", as used "herein, encompasses any infection, disease or other disorder of body, typically of the upper and/or lower gastrointestinal tract, caused or mediated by one or more intestinal helminths. Such disorders include one or more of the following conditions: diarrhea- abdominal pain and/or cramping, epigastric fullness, constipation, blood and/or mucus present in feces, fever, vomiting, gastroenteritis, weight loss, anemia, malaise, pallor, anal pruritus, and any other condition commonly associated with infection by intestinal helminths. Severe infections may even result in dangerous migrations of infection to ectopic sites such as the liver, lungs, etc. or even death. In immunocompromised subjects and children, gastrointestinal disorders caused or mediated by intestinal helminths may be more severe and life threatening than the common disorders listed above. Therefore, the term "gastrointestinal disorder" also includes any condition commonly associated with intestinal helminths in immunocompromised subjects and children, including but not limited to bloody diarrhea, extreme constipation, irritability, extreme pruritus, wasting, listlessness, bowel obstruction, and retardation of development. Intestinal Helminths Intestinal helminths, commonly referred to as worms, are multi-cellular parasites which have been implicated in intestinal disease. The term "intestinal helminths", as used herein, refers to helminths of the following medically important groups: Nematodes, Trematodes, and Cestodes. These organisms are fully described in Zinsser Microbiology. 20th Edition, 1 195-1215, (1992) and Manual of Clinical Microbiology. Sixth Edition, 1141-1144, and 1229-1243, (1995), both of which are incorporated herein by reference. Nematodes (or roundworms) include Trichinella spiralis, Enterobius ver- micularis (pinworm), Ascaris lumbricoides, Trichuris trichiura (whipworm), Capillaria philippinensis, Ancylcolostoma duodenale (common hookworm), Necator amehcanus (American hookworm), and Trichostrongylus (species such as Strongyloides stercoralis (threadworm). Trematodes (fluke worms) include Fasciolopsis buski, Heterophyes heterophyes, Metagoniumus yokogawai, and Nanophyetus salmincola. Cestodes (or tapeworms) include Diphyllobothrium latum, Tae ia saginata, T enia solium, and Hymenolepis nana. Preferred intestinal helminths are Enter obius vermicular is, Ancylostoma duodenale, Trichuris trichiura, Fasciolopsis buski, Trichostrongylus species, Taenia saginata, and combinations thereof. Most preferred parasitic protozoa are Enterobius vermicularis, Ancylostoma duodenale, Trichuris trichiura, and combinations thereof. Diagnosis of gastrointestinal disorders caused or mediated by intestinal helminths may be accomplished by any method commonly used in the medical community. Such methods are fully described in Zinsser Microbiology, and Manual of Clinical Microbiology, as referenced above. BismutJ The methods of treatment and/or prevention in the present invention involve administration of bismuth. As used herein, the quantity of bismuth is by weight of elemental bismuth. The preferred duration of bismuth administration will vary according to the specific gastrointestinal disorder to be treated and the physical condition of the subject being treated. In general, as a method of treatment, bismuth may be administered in an amount of from about 50 milligrams to about 5000 milligrams, and preferably from about 50 milligrams to about 2500 milligrams, per day, for from about 1 to about 56 days, preferably for from about 2 to about 28 days, and most preferably for from about 7 to about 21 days. In general, as a method of prevention, bismuth may be administered in an amount of from about 50 milligrams to about 5000 milligrams, and preferably from about 50 milligrams to about 2500 milligrams, per day, for from about 1 to about 21 days, and preferably for from about 1 to about 14 days. In a method of prevention, bismuth may be administered prior to potential exposure to intestinal helminths. Such administration of bismuth may vary depending on the likelihood of intestinal helminth exposure and condition of the subject and may be commenced at any time deemed beneficial by the medical community including from about 1 to about 7 days, from about 2 to about 5 days, and from about 3 to about 4 days, prior to potential exposure. In the present invention, the term "bismuth", as used herein, includes bis¬ muth in the form of a pharmaceutically-acceptable salt, bismuth in the form of an organic or other complex which contains bismuth as an active ingredient, and mixtures thereof. Such organic complexes include 2,2'-spirobi[l,3,2- benzodoxabismole]. Preferably, bismuth is administered in the present methods as a pharmaceutically-acceptable salt. Such bismuth salts include bismuth aluminate, bismuth subcarbonate, bismuth subcitrate, bismuth citrate, tripotassium dicitrato bismuthate, bismuth subgalate, bismuth subnitrate, bismuth tartrate, bismuth subsalicylate, and mixtures thereof. Bismuth citrate, bismuth subcitrate, tripotassium dicitrato bismuthate, bismuth tartrate, bismuth subsalicylate, and mixtures thereof are preferred bismuth salts for use in this invention. The bismuth useful herein may be administered alone, or in combination with other pharmaceutically-acceptable components in a bismuth-containing composition. A variety of such compositions containing bismuth salts are commercially available. Such compositions include DeNol, containing tripotassium dicitrato bismuthate (by Brocades); Bislumina, containing bismuth aluminate (by Mazuelos); Roter, containing bismuth subnitrate (by Roterpharma); Devrom®, containing bismuth subgallate (by The Parthenon Co., Inc.); and Pepto-Bismol®, containing bismuth subsalicylate (by The Procter & Gamble Company). As used herein, the term "administering" refers to any method which, in sound medical practice delivers the compounds or compositions used in this invention to the subject to be treated in such a manner so as to be effective in the treatment ofthe gastrointestinal disorder. Preferably, the bismuth is administered orally. The following non-limiting examples illustrate the methods and uses of the present invention. EXAMPLE I A South African farmer enters a health clinic in an extremely weakened condition with sallow skin and a tender abdomen, describing periods of alternating diarrhea and constipation. Fecal bacterial isolates fail to identify the offending pathogen. Direct wet mount examination of the fecal specimens reveals the presence of thin shelled eggs (40-60 m) which confirms the diagnosis of Ancylostoma duodenale. Following the diagnosis, the patient is treated by administering a composition containing bismuth subsalicylate, sold by The Procter & Gamble Company under the name "Pepto-Bismol®". The composition, in liquid form, is administered four times daily in equal doses delivering approximately 2500 milligrams of bismuth per day, for 21 days. Thereafter, fecal samples from the subject are analyzed again, finding no trace of helminthic infection. The patient remains asymptomatic, and another fecal analysis performed 5 months later is normal. In the above example, tripotassium dicitrate bismuthate tartrate, bismuth citrate, and bismuth subnitrate are substituted, respectively, for bismuth subsalicylate, with substantially similar results. EXAMPLE II A five-year-old child, from an indigent Appalachian family, is suffering from nausea, vomiting, and mucous diarrhea. Analysis of fecal specimens reveals the presence of barrel shaped eggs (20-50 m in size, golden brown in color, and having a transparent prominence or polar plug at each end), characteristic of Trichuris trichiura. The infection is diagnosed and treated by orally administering approximately 400 milligrams of bismuth in the form of bismuth subcitrate ("DeNol" sold by Brocades), in four equal doses daily for about 28 days. Thereafter, fecal samples from the subject are analyzed again, finding no trace of helminthic infection. EXAMPLE III Eight children in a kindergarten class of twelve students have been diag¬ nosed with pinworms. The parents of the four uninfected children solicit help from the student health service to prevent their children from becoming infected with Enterobius vermicularis. Clinical evaluation of the four children confirms that they had not been infected. The children are given approximately 800 milligrams of bismuth, in the form of bismuth subgalate (Devrom®, sold by The Parthenon Company, Inc.), in four equal doses daily for about 21 days. The four children remain asymptomatic. Fecal samples from all children of the kindergarten class are analyzed and no evidence of pinworm infection is found.

Claims: What is claimed is: 1. The use of from 50 milligrams to 5000 milligrams of bismuth per day for from 1 to 56 days for the manufacture of a composition for the treatment of a gastrointestinal disorder caused or mediated by one or more intestinal helminths. 2. The use according to Claim 1 wherein the bismuth is administered at a level of from about 50 milligrams to about 2500 milligrams, per day. 3. The use according to Claim 1 or 2 wherein the bismuth is selected from the group consisting of bismuth aluminate, bismuth subcarbonate, bismuth subcitrate, bismuth citrate, tripotassium dicitrato bismuthate, bismuth subgalate, bismuth subsalicylate, bismuth tartrate, and mixtures thereof. 4. The use according to any of Claims 1-3 wherein the intestinal helminths are selected from the group consisting of Enterobius vermicularis, Ancylostoma duodenale, Trichuris trichiura, Fasciolopsis buski, Trichostrongylus species, Taenia saginata, and combinations thereof. 5. The use according to any of Claims 1-4 wherein said bismuth prevents a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering to the subject from 50 milligrams to 5000 milligrams of bismuth per day, for from 1 to 21 days. 6. The use according to any of Claims 1-5 wherein the bismuth is administered at a level of from about 50 milligrams to about 2500 milligrams, per day.

Inventors: FITZGERALD JAMESINA ANNE, FITZGERALD, JAMESINA, ANNE
Applicants: PROCTER & GAMBLE, THE PROCTER & GAMBLE COMPANY
Application year: 1996
Main classification: A61K33
IPC codes: A61K31, A61K33